Peritoneal Dialysis Market

The peritoneal dialysis market is projected to reach USD 14.16 billion in 2031 from USD 10.04 billion in 2026 at a CAGR of 6.0%. The increasing prevalence of CKD, primarily due to diabetes and hypertension, has increased the patient population requiring dialysis. There is an increasing demand for peritoneal dialysis. Diabetes and hypertension are some of the top causes of CKD. They are responsible for over two-thirds of all cases worldwide. The increasing rates of these diseases are due to changing lifestyles, the aging population, and increased rates of obesity. Consequently, more patients are diagnosed with CKD, followed by advancement into ESRD. It is from this stage that PD becomes a very viable form of dialysis treatment for patients; the process does not require conventional clinical attendance in the way of patients diagnosed to undergo hemodialysis. Presently, PD is rapidly catching the enthusiasm because it has flexibility, is cost-effective, and gives patients a better quality of life, as the procedure can now be done at home, and more mobility is possible. Moreover, with the arrival of new technologies in PD, including those automated PD systems and catheters, the practice is getting even more accessible, making it even more efficient, and still supports growth. Such an increase in demand for PD is facilitated by government health programs and reimbursement policies, with the ultimate aim to make dialysis accessible and affordable for the increasing population of CKD patients.

In this report, the peritoneal dialysis market has been segmented on the basis of offering, modality, disease indication, end user, and region.

To know about the assumptions considered for the study download the pdf brochure

Prominent players in this market include Vantive (US), Fresenius Medical Care AG (Germany), Mozarc Medical (US), Davita Inc. (US), Becton, Dickinson and Company (US), Utah Medical Products, Inc. (US), Terumo Corporation (Japan), Diaverum AB (Sweden), Medionics (Canada), Newsol Technologies (Canada), Apollo Dialysis Pvt Ltd (India), U.S. Renal Care, Inc. (US), Northwest Kidney Centers (US), Relavo (US), Mitra Industries Pvt Ltd (India), JMS Co., Ltd. (Japan), AMECATH (Egypt), Polymedicure (India), Huaren Pharmaceutical (China), AWAK Technologies (Singapore), Innovative Renal Care (US), Romsons (India), SSEM Mthembu Medical (Pty) Ltd (South Africa),  Renax Biomedical Technology Co., Ltd (China), and Advin Health Care (India).

Fresenius Medical Care AG (Germany)

Fresenius Medical Care is one of the largest peritoneal dialysis players in the world. The company differs according to its comprehensive portfolio of dialysis products, remarkable R&D, and presence around the globe. The company operates through 42 facilities in Asia Pacific, North America, Europe, Latin America, and Africa, keeping a focus on partnership and agreement to seek further opportunities. Fresenius puts emphasis on the advanced dialysis products of renal therapies in developing the treatments for kidney disease. This further reinforces its market position. It focuses on purchases and acquisitions as well, as in the case of acquiring InterWell Health in 2022, which guides the drive towards innovation. The company operated 4,116 dialysis clinics at year-end 2022. Fifteen percent of U.S. patients are being treated in a home setting, increasing to 25% by 2025. Fresenius invests its R&D in innovative products, regenerative medicines, and the use of digital technologies such as data analytics and remote monitoring to optimize dialysis care.

Vantive (US)

Vantive is a global kidney care company established in 2025 following the separation of Baxter's Kidney Care business. The company offers one of the industry's broadest portfolios of peritoneal dialysis (PD) therapies, including automated peritoneal dialysis (APD), continuous ambulatory peritoneal dialysis (CAPD), PD cyclers, transfer sets, dialysis solutions, and remote patient management technologies. Leveraging decades of expertise inherited from Baxter, Vantive serves patients across more than 100 countries through an extensive manufacturing and distribution network. The company focuses on advancing home-based kidney care by improving treatment accessibility, patient outcomes, and digital connectivity. Vantive continues to invest in innovation through the integration of connected care platforms, data-driven clinical decision support, and next-generation PD technologies that enhance therapy adherence and monitoring. The company is also expanding strategic partnerships with healthcare providers to strengthen home dialysis adoption and improve patient education programs. With a dedicated focus on kidney care following its separation, Vantive is well-positioned to capitalize on the growing demand for home-based dialysis solutions, particularly in the peritoneal dialysis market, where increasing prevalence of chronic kidney disease, favorable reimbursement policies, and the shift toward value-based care continue to drive market growth.

DaVita Inc. (US)

DaVita Inc. is one of the world's leading kidney care providers, delivering comprehensive dialysis services through an extensive network of dialysis centers while expanding its home-based care portfolio. The company offers peritoneal dialysis as a key home dialysis modality, supported by patient education, clinical training, remote monitoring, and multidisciplinary care programs to improve treatment adherence and outcomes. DaVita continues to invest in digital health technologies, care coordination, and value-based kidney care models that enhance patient experience and reduce healthcare costs. The company collaborates with healthcare providers, payers, and technology partners to increase access to home dialysis and promote earlier adoption of PD among eligible patients. Through initiatives focused on patient-centric care, clinical innovation, and operational excellence, DaVita is strengthening its position in the peritoneal dialysis market. The company also benefits from favorable reimbursement policies, growing awareness of home dialysis, and the increasing prevalence of chronic kidney disease and end-stage kidney disease. These strategic initiatives, combined with its strong clinical expertise and global kidney care experience, position DaVita as a significant participant in the expanding global peritoneal dialysis market.

Market Ranking

The peritoneal dialysis market is competitive, with prominent players accounting for 70.0% of the total market share in 2025. Some of the players dominating the market include Fresenius Medical Care AG (Germany), Terumo Corporation (Japan), Davita Inc. (US), Vantive (US), and Becton, Dickinson and Company (US), among others.

Global leaders in the peritoneal dialysis market have historically focused on developed regions such as North America, Western Europe, and Japan, supported by robust renal-care infrastructure, high awareness of home dialysis, and favorable reimbursement policies. These markets continue to drive stable demand for PD solutions. However, emerging economies across Asia–Pacific, Latin America, the Middle East, and Eastern Europe are gaining traction as healthcare access improves and cost pressures rise. Regional manufacturers are entering with competitively priced PD consumables, catheters, and access devices tailored to local needs. Coupled with growing emphasis on home-based care, telehealth, and value-based models, this shift is creating new growth opportunities globally.

Related Reports:

Peritoneal Dialysis Market by Offering (Peritoneal Dialysis Solution Bags, Machines), Modality (Continuous Ambulatory Peritoneal Dialysis Center(CAPD)), Disease Indication (End-Stage Renal Disease), End User (Hospitals)- Global Forecast to 2031

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
[email protected]